Find and Pitch Jounalists, Get Your Story Covered

	Profile	Recent Articles on Subject
1	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	New First-Line Option for Advanced ALK-Positive Lung Cancer - 8 days ago FDA Approves Zanidatamab for Biliary Tract Cancer - about 1 month ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 4 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 4 months ago Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutations - about 1 year ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - about 1 year ago RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC - about 1 year ago
2	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Advances in ALL at ASH Meeting Include New Blinatumomab Data and More - 8 days ago TIL Therapy May Offer Novel Approach for Metastatic Lung Cancer - 6 months ago Pirtobrutinib Shows Potential in Heavily Pretreated Follicular Lymphoma - 12 months ago Novel Doublet Highly Effective in Low-Grade Serous Ovarian Cancer - about 1 year ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - about 1 year ago New Data on TYK2 Inhibitors for Psoriasis, Psoriatic Arthritis - about 1 year ago Anti-TIGIT Drug Fails to Lift Response Rates in Cervical Cancer Trial - about 1 year ago
3	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Novel BTK Inhibitor Succeeds in Heavily Pretreated Immune Thrombocytopenia - 18 days ago Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study - 7 months ago FDA Approves New Frontline Regimen for Aggressive ALL - 9 months ago FDA OKs Amivantamab as First-Line Lung Cancer Treatment - 10 months ago JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - about 1 year ago Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia - about 1 year ago Non-Covalent BTK Inhibitor Approved for CLL - about 1 year ago Lymphoma Drug Copanlisib to Be Pulled From U.S. Market - about 1 year ago New Oral Drug Approved for Metastatic Colorectal Cancer - about 1 year ago New Options Challenge Standard Treatments in EGFR-Mutant NSCLC - about 1 year ago Randomized Trial Backs HIF-2a Inhibition in Advanced RCC - about 1 year ago
4	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Antibody Drug Conjugate Targeting CLDN1 Receives FDA Fast Track Designation - about 1 month ago CHMP Recommends Lazertinib With Amivantamab to Treat EGFR-Mutated Advanced NSCLC - about 1 month ago Zaltenibart Receives FDA Rare Pediatric Disease Designation for C3 Glomerulopathy - 2 months ago Jazz Pharmaceuticals Submits Biologics License Application for Zanidatamab to Treat Biliary Tract Cancer - 9 months ago Adagrasib Meets Primary Endpoint Among Individuals with KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC - 9 months ago
5	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	MHRA grants approval for bladder cancer drug erdafitinib - about 2 months ago
6	Kristen Monaco MedPage Today	Complement Inhibitor Shows Promise for Rare Kidney Disorder - about 2 months ago Interim ALIGN Data: Atrasentan Cuts Proteinuria in IgA Nephropathy - 2 months ago Alternative Pathway Inhibition Makes Good in IgA Nephropathy - 2 months ago
7	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Astellas Pharma Lands a First-in-Class Drug Approval in Rare Gastrointestinal Cancer - 2 months ago
8	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Accepts NDA and Priority Review Application for Vimseltinib in Tenosynovial Giant Cell Tumors - 4 months ago FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - 4 months ago FDA Grants Priority Review for Asciminib for Chronic Myeloid Leukemia - 5 months ago FDA Grants Fast Track Designation to Potential Treatment for Clear Cell Renal Cell Carcinoma - 6 months ago FDA Accepts Supplemental New Drug Application for Adagrasib for Colorectal Cancer - 10 months ago FDA Grants Orphan Drug Designation to Tigilanol Tiglate for Soft Tissue Sarcoma - 10 months ago FDA Approves Belzutifan for Treatment of Advanced Renal Cell Carcinoma - about 1 year ago FDA Approves Capivasertib With Fulvestrant for PIK3CA/ALT1/PTEN Alterations Breast Cancer - about 1 year ago FDA Approves Repotrectinib for Treatment of ROS1-Positive NSCLC - about 1 year ago TAK-279 Demonstrates Improvements in ACR 20 Response for Psoriatic Arthritis - about 1 year ago FDA Grants Priority Review to New Drug Application for Belzutifan for Advanced Renal Cell Carcinoma - over 1 year ago
9	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Axatilimab-csfr for cGVHD - 4 months ago
10	Judy George MedPage Today Medical reporter, writer. Medical reportingartsliterature	ALS Therapy to Be Pulled From the Market, Drugmaker Says - 9 months ago

Journalists covering alectinib